Upcoming Webinar:Join us for Sustainability 100+ Dialogues 2021-Maharashtra Roundtable& know how the state is progressing on climate action
you are here: HomeNewsBusiness

Unichem Laboratories gets USFDA nod for plaque psoriasis treatment drug

Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

February 19, 2021 / 11:19 AM IST
Aurobindo Pharma | The company reported sharply higher profit at Rs 2,946.3 crore in Q3FY21 against Rs 705.3 crore in Q3FY20, revenue rose to Rs 6,364.9 crore from Rs 5,895 crore YoY.

Aurobindo Pharma | The company reported sharply higher profit at Rs 2,946.3 crore in Q3FY21 against Rs 705.3 crore in Q3FY20, revenue rose to Rs 6,364.9 crore from Rs 5,895 crore YoY.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Drug firm Unichem Laboratories on Friday said it has received approval from the US health regulator to market Apremilast tablets, used for treatment of plaque psoriasis.

Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

The company has received abbreviated new drug application (ANDA) approval to market its Apremilast tablets in the strengths of 10 mg, 20 mg and 30 mg from the United States Food and Drug Administration (USFDA), Unichem Labs said in a regulatory filing.

The approved product is a generic version of Amgen''s Otezla tablets.

Shares of Unichem Labs were trading 1.36 percent higher at Rs 309.75 apiece on BSE.
PTI
first published: Feb 19, 2021 11:20 am

stay updated

Get Daily News on your Browser
Sections
ISO 27001 - BSI Assurance Mark